AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Investment analysts at HC Wainwright issued their Q2 2027 earnings per share estimates for AnaptysBio in a report issued on Friday, November 13th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will earn $0.38 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $95.00 target price on the stock. The consensus estimate for AnaptysBio's current full-year earnings is ($1.30) per share.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Thursday, November 12th. The biotechnology company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of ($1.84) by $1.95. AnaptysBio had a negative return on equity of 14.28% and a net margin of 96.30%. The company had revenue of $30.27 million during the quarter, compared to analyst estimates of $25.56 million.
Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of AnaptysBio in a report on Tuesday, September 22nd. Wolfe Research reaffirmed an "outperform" rating and issued a $78.00 target price on shares of AnaptysBio in a research note on Monday, August 31st. Weiss Ratings reiterated a "sell (e+)" rating on shares of AnaptysBio in a research report on Wednesday, November 4th. JPMorgan Chase & Co. decreased their price target on shares of AnaptysBio from $70.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, September 30th. Finally, TD Cowen decreased their price target on shares of AnaptysBio from $75.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday, August 25th. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $75.67.
View Our Latest Research Report on ANAB
AnaptysBio Stock Down 1.1%
Shares of NASDAQ ANAB opened at $45.73 on Tuesday. The firm's 50-day simple moving average is $49.57 and its 200 day simple moving average is $56.29. The company has a market cap of $1.37 billion, a price-to-earnings ratio of 9.22 and a beta of 0.70. AnaptysBio has a 12-month low of $22.01 and a 12-month high of $72.36.
Institutional Trading of AnaptysBio
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tema ETFs LLC grew its position in shares of AnaptysBio by 0.6% during the 2nd quarter. Tema ETFs LLC now owns 31,270 shares of the biotechnology company's stock worth $2,111,000 after buying an additional 201 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its holdings in AnaptysBio by 2.3% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 17,650 shares of the biotechnology company's stock valued at $887,000 after buying an additional 400 shares during the period. Arizona State Retirement System lifted its holdings in AnaptysBio by 13.5% in the second quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company's stock valued at $295,000 after buying an additional 518 shares during the period. Persistent Asset Partners Ltd bought a new position in AnaptysBio in the second quarter valued at approximately $39,000. Finally, Sterling Capital Management LLC boosted its stake in AnaptysBio by 847.8% in the third quarter. Sterling Capital Management LLC now owns 654 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 585 shares during the last quarter.
Insider Buying and Selling at AnaptysBio
In other news, Director Hollings Renton sold 5,000 shares of the business's stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $49.87, for a total transaction of $249,350.00. Following the completion of the sale, the director owned 10,995 shares in the company, valued at $548,320.65. The trade was a 31.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 31.50% of the stock is currently owned by insiders.
AnaptysBio Company Profile
(
Get Free Report)
AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company's pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AnaptysBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.
While AnaptysBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.